Financial Performance - Product revenue for the three months ended September 30, 2023, was $18.461 million, a decrease from $19.954 million in the same period last year, representing a decline of approximately 7.5%[17] - Total revenues for the nine months ended September 30, 2023, were $61.190 million, compared to $61.456 million for the same period last year, indicating a slight decrease of about 0.4%[17] - The net loss for the three months ended September 30, 2023, was $6.998 million, compared to a net loss of $7.747 million in the same period last year, showing an improvement of approximately 9.7%[17] - The comprehensive loss for the three months ended September 30, 2023, was $8.081 million, compared to a comprehensive loss of $6.941 million in the same period last year, indicating a decline of about 16.4%[17] - The company reported a net loss per share of $0.16 for the three months ended September 30, 2023, compared to a net loss per share of $0.18 in the same period last year[17] - The net loss for the nine months ended September 30, 2024, was $22,876,000, an increase from a net loss of $20,439,000 for the same period in 2023[22] - The net loss for the three months ended September 30, 2024, was $6,998,000, compared to a net loss of $7,747,000 for the same period in 2023, indicating an improvement of 9.7%[52] - The net loss for the nine months ended September 30, 2024, was $22.8 million, compared to a net loss of $20.4 million in 2023, reflecting a 12% increase in losses[159] Expenses - Research and development expenses for the three months ended September 30, 2023, were $11.168 million, down from $15.358 million in the prior year, reflecting a decrease of approximately 27%[17] - Selling, general, and administrative expenses increased to $13.613 million for the three months ended September 30, 2023, compared to $10.200 million in the same period last year, marking an increase of about 33.6%[17] - Research and development expenses decreased by $4.2 million, or 27%, to $11.2 million for the three months ended September 30, 2024, compared to $15.4 million in 2023[145] - Selling, general, and administrative expenses increased by $3.4 million, or 33%, to $13.6 million for the three months ended September 30, 2024[145] - Total operating costs and expenses increased to $86.4 million for the nine months ended September 30, 2024, from $83.9 million in 2023, an increase of 3%[159] Cash and Liquidity - Cash and cash equivalents decreased to $68,122,000 as of September 30, 2024, from $78,637,000 as of December 31, 2023[29] - The company expects that its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures for at least the next 12 months[29] - Cash and cash equivalents were $68.1 million as of September 30, 2024, down from $78.6 million as of December 31, 2023[176] - Net cash used in operating activities decreased by $5.4 million, or 28%, to $13.84 million for the nine months ended September 30, 2024, compared to $19.2 million for the same period in 2023[178] - Net cash provided by financing activities was $3.3 million for the nine months ended September 30, 2024, resulting from proceeds from exercised stock options[182] Equity and Stock - Total stockholders' equity decreased to $92.429 million as of September 30, 2023, down from $100.985 million at the end of the previous year, representing a decline of approximately 8.4%[15] - The Company has authorized a total of 105,500,000 shares, with 44,766,802 shares of common stock issued as of September 30, 2024[83][84] - The Company had 10,043,999 stock options outstanding, with a weighted average exercise price of $17.55[95] - Total stock-based compensation expense for the three months ended September 30, 2024 was $4,195,000, an increase of 74% compared to $2,410,000 for the same period in 2023[88] Revenue Sources - The company has funded operations primarily through proceeds from sales of common stock and revenue from DANYELZA sales[28] - Royalty revenue from distribution partners was $1,133,000 for the three months ended September 30, 2024, compared to $427,000 in the same period of 2023, marking a significant increase of 165%[48] - License revenue was $0 for the three months ended September 30, 2024, compared to $0.5 million in the same period of 2023[148] - License revenue remained flat at $0.5 million for both the nine months ended September 30, 2024, and 2023, related to regulatory-based milestone payments[164] Inventory and Assets - Total inventories increased to $27,048,000 as of September 30, 2024, from $17,013,000 as of December 31, 2023, representing a 59.3% increase[53] - The company did not record any inventory write-offs during the three and nine months ended September 30, 2024, contrasting with write-offs of $375,000 and $831,000 for the same periods in 2023[56] - Intangible assets related to DANYELZA amounted to $2,366,000 net as of September 30, 2024, down from $2,631,000 as of December 31, 2023, reflecting a decrease of 10.1%[58] Strategic Developments - The company completed a strategic restructuring plan in May 2023, resulting in a 35% reduction in workforce and recognizing restructuring expenses of $4,482,000 for the nine months ended September 30, 2023[14] - The company has deprioritized the development of radiolabeled omburtamab for CNS-LM and other pipeline programs to focus on DANYELZA and the SADA PRIT platform[123] - A license agreement with Nobelpharma Co., Ltd. for DANYELZA in Japan was signed on October 29, 2024, entitling the company to a non-refundable payment of $2,000,000 and up to $31,000,000 in milestone payments[15] Clinical Trials and Product Development - DANYELZA received accelerated approval from the FDA in November 2020 and is currently being commercialized in the United States, with a patent extension achieved through February 2034[110] - The ongoing pivotal-stage multicenter trial for DANYELZA is designed to satisfy FDA's accelerated approval confirmatory study requirements[111] - The company has 22 active sites in a multi-center Phase 2 trial evaluating naxitamab in combination with standard induction therapy for newly diagnosed high-risk neuroblastoma patients[113] Regulatory and Compliance - The company evaluated the effectiveness of its disclosure controls and procedures as of September 30, 2024, concluding they were effective at a reasonable assurance level[193] - There were no changes in internal control over financial reporting during the quarter ended September 30, 2024, that materially affected or are likely to materially affect internal control over financial reporting[195]

Revenue Performance - Total DANYELZA net product revenues for Q3 2024 were $18.5 million, a 10% decline from $20.5 million in Q3 2023[4] - U.S. DANYELZA net product revenues were $15.3 million for Q3 2024, down 5% from $16.1 million in Q3 2023, primarily due to an unfavorable price mix[6] - Ex-U.S. DANYELZA net product revenues for Q3 2024 were $3.1 million, a 19% decline from $3.9 million in Q3 2023, driven by decreased volume from Western Europe[7] - Total revenues for the three months ended September 30, 2024, were $18,461,000, a decrease of 9.7% compared to $20,454,000 for the same period in 2023[26] - Product revenue for the nine months ended September 30, 2024, was $60,690,000, slightly down from $60,956,000 in the same period of 2023[26] Expenses - Research and development expenses for Q3 2024 were $11.2 million, a decrease of $4.2 million compared to Q3 2023[12] - Selling, general, and administrative expenses for Q3 2024 were $13.6 million, an increase of $3.4 million from $10.2 million in Q3 2023[14] - Research and development expenses for the three months ended September 30, 2024, were $11,168,000, compared to $15,358,000 for the same period in 2023, indicating a decrease of 27.1%[26] - Selling, general, and administrative expenses increased to $13,613,000 for the three months ended September 30, 2024, up from $10,200,000 in the same period of 2023, a rise of 33.7%[26] Net Loss and Financial Position - The company reported a net loss of $7.0 million for Q3 2024, compared to a net loss of $7.7 million in Q3 2023[18] - The net loss for the three months ended September 30, 2024, was $6,998,000, compared to a net loss of $7,747,000 for the same period in 2023, reflecting a 9.7% improvement[26] - The company reported a comprehensive loss of $8,081,000 for the three months ended September 30, 2024, compared to a comprehensive loss of $6,941,000 for the same period in 2023[26] Cash and Assets - As of September 30, 2024, the company had approximately $68.1 million in cash and cash equivalents, with cash utilized in the first three quarters of 2024 being $10.5 million[20] - Cash and cash equivalents decreased to $68,122,000 as of September 30, 2024, from $78,637,000 at the end of 2023, representing a decline of 13.3%[25] - Total current assets decreased to $99,057,000 as of September 30, 2024, down from $111,111,000 at December 31, 2023, a reduction of 10.9%[25] Liabilities - Total liabilities increased to $28,488,000 as of September 30, 2024, from $26,884,000 at December 31, 2023, an increase of 5.9%[25] Future Plans and Guidance - Management reiterated full year 2024 guidance with anticipated total net revenues between $87 million and $95 million[21] - The company plans to transition its headquarters to Princeton, New Jersey, in the first half of 2025[3] Share Information - The weighted average common shares outstanding for the three months ended September 30, 2024, were 44,626,943, compared to 43,620,532 for the same period in 2023[26] Licensing Agreement - The company entered into an exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan, recognizing an upfront payment of $2.0 million in Q4 2024[3]

The market expects Y-mAbs Therapeutics, Inc. (YMAB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expect ...

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these resu ...

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that its management team will participate in the following upcoming investor conferences: Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit Date: Tuesday, October 8, 2024 T ...

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented ...

The company didn't quite meet expectations for either trailing results or full-year guidance. Cancer drug developer Y-mAbs Therapeutics (YMAB -11.24%) didn't exactly kick off the stock trading week on a high note. The company's shares closed the day more than 11% lower in price, following the release of its latest set of quarterly results. That contrasted unfavorably with the performance of the bellwether S&P 500 index, which flatlined that session. A double miss for the second quarter Y-mAbs is a commercia ...

simonkr Topline Summary and Update Y-mAbs Therapeutics (NASDAQ:YMAB) has maintained something of a holding pattern in terms of market valuation after my last article published in May 2024. Now, we've seen some updates coming out of summer meetings, as well as new financial filings for the company. Still sitting at a market cap of nearly $500 million, YMAB continues to be priced in line with a mid-stage clinical biotech, as opposed to being a commercial-stage entity, and today I want to take a look to see if ...

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -61.54%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.15, delivering a surprise of -25%. Over the last four quarters, the company h ...

Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong Kong Part A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024 Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran ...